<DOC>
	<DOCNO>NCT00110903</DOCNO>
	<brief_summary>The purpose study assess safety etanercept liquid administer weekly subject RA .</brief_summary>
	<brief_title>Treatment Subjects With Active Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Fulfill 1987 American Rheumatism Association ( ARA ) criteria RA Active RA time enrollment , receipt concomitant methotrexate dose 25 mg week permit Screening lab result must demonstrate : AST ALT less equal 2 time upper limit normal hemoglobin great equal 8.5 g/dL ; Platelet count great equal 125,000/cm3 ; White blood cell count ( WBC ) great equal 3500 cells/cm3 ; Serum creatinine less equal 2 mg/dL Before study specific procedure perform , subject must provide informed consent participation study Previous receipt etanercept Receipt antibody ( tumor necrosis factor ) TNF alpha TNF inhibitor within 90 day Day 1 Currently enrol investigational device drug trial , participation investigational trial within past 30 day Receipt intraarticular corticosteroid within 14 day prior Day 1 Receipt diseasemodifying antirheumatic drug ( DMARDs ) within 28 day Day 1 Receipt cyclophosphamide within 6 month Day 1 Concomitant corticosteroid great 10 mg/day prednisone ( equivalent ) 14 day prior Day 1 Dose nonsteroidal antiinflammatory drug ( NSAID ) must stable 14 day prior Day 1 must exceed recommend dose product information sheet Subject use adequate contraception Subject pregnant breastfeeding Subject significant concurrent medical disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>RA</keyword>
	<keyword>etanercept</keyword>
	<keyword>Immunex</keyword>
	<keyword>Amgen</keyword>
</DOC>